[1]徐武,程利华,张礼平,等.紫车散外敷联合塞来昔布胶囊口服治疗湿热瘀闭型膝关节滑膜炎的临床研究[J].中医正骨,2017,29(10):30-34.
　XU Wu,CHENG Lihua,ZHANG Liping,et al.Clinical study on external application of Ziche San(紫车散)combined with oral application of celecoxib capsules for treatment of gonarthromeningitis with syndrome of BLOCKADE of DAMP-HEAT and STATIC BLOOD[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(10):30-34.
点击复制

紫车散外敷联合塞来昔布胶囊口服治疗湿热瘀闭型膝关节滑膜炎的临床研究()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第29卷
期数:
2017年10期
页码:
30-34
栏目:
临床研究
出版日期:
2017-10-20

文章信息/Info

Title:
Clinical study on external application of Ziche San(紫车散)combined with oral application of celecoxib capsules for treatment of gonarthromeningitis with syndrome of BLOCKADE of DAMP-HEAT and STATIC BLOOD
作者:
徐武1; 程利华1; 张礼平2; 秦鹏俊3; 刘德玉4; 朱立国5
1.陕西中医药大学,陕西 咸阳 712046; 2.陕西中医药大学第二附属医院,陕西 咸阳 712000; 3.陕西省商洛市中医医院,陕西 商洛 726000; 4.陕西中医药大学附属医院,陕西 咸阳 712046; 5.中国中医科学院望京医院,北京 100102
Author(s):
XU Wu1; CHENG Lihua1; ZHANG Liping2; QIN Pengjun3; LIU Deyu4; ZHU Liguo5
1.Shanxi University of Chinese Medicine,Xianyang 712046,Shanxi,China 2.The Second Affiliated Hospital of Shanxi University of Chinese Medicine,Xianyang 712000,Shanxi,China 3.Shangluo Hospital of Traditional Chinese Medicine,Shangluo 726000,Shanxi,China 4.The Affiliated Hospital of Shanxi University of Chinese Medicine,Xianyang 712046,Shanxi,China 5.Wangjing Hospital of China Academy of Chinese Medical Sciences,Beijing 100102,China
关键词:
滑膜炎;  膝关节;  紫车散;  塞来昔布胶囊;  湿热瘀闭;  临床试验
Keywords:
Key words synovitis;  knee joint;  Ziche San;  Celecoxib capsules;  syndrome of blockade of damp-heat and static blood;  clinical trail
摘要:
目的:观察紫车散外敷联合塞来昔布胶囊口服治疗湿热瘀闭型膝关节滑膜炎的临床疗效和安全性。方法:将63例符合要求的湿热瘀闭型膝关节滑膜炎患者随机分为2组,联合治疗组28例、塞来昔布组35例。联合治疗组采用紫车散外敷联合塞来昔布胶囊口服治疗,塞来昔布组单纯采用塞来昔布胶囊口服治疗,共治疗4周。分别于治疗前和治疗结束后测定患者的红细胞沉降率(erythrocyte sedimentation rate,ESR)、超敏C反应蛋白(hypersensitive C-reactive protein,hs-CRP)水平、膝关节疼痛视觉模拟量表(visual analogue scale,VAS)评分及Lysholm膝关节评分,观察患者治疗期间的并发症发生情况。结果:治疗前2组患者的ESR比较,差异无统计学意义(t=0.077,P=0.567); 治疗结束后2组患者的ESR均降低[(36.04±11.04)mm·h-1,(11.61±6.30)mm·h-1,t=13.818,P=0.000;(34.37±11.02)mm·h-1,(17.23±7.45)mm·h-1,t=10.411,P=0.000],联合治疗组的ESR低于塞来昔布组(t=1.480,P=0.002)。治疗前2组患者的hs-CRP水平比较,差异无统计学意义(t=0.201,P=0.691); 治疗结束后2组患者的hs-CRP水平均降低[(40.57±11.73)mg·L-1,(7.39±2.31)mg·L-1,t=15.599,P=0.000;(39.37±11.96)mg·L-1,(16.91±6.68)mg·L-1,t=9.936,P=0.000],联合治疗组的hs-CRP水平低于塞来昔布组(t=26.264,P=0.000)。治疗前2组患者的膝关节疼痛VAS评分比较,差异无统计学意义(t=0.129,P=0.657); 治疗结束后2组患者的VAS评分均降低[(6.54±1.62)分,(1.93±0.22)分,t=10.827,P=0.000;(6.71±1.55)分,(2.74±0.60)分,t=13.398,P=0.000],联合治疗组的VAS评分低于塞来昔布组(t=2.333,P=0.029)。治疗前2组患者的Lysholm膝关节评分比较,差异无统计学意义(t=0.306,P=0.826); 治疗结束后2组患者的Lysholm评分均增大[(54.04±12.56)分,(82.36±7.99)分,t=-8.908,P=0.000;(54.71±11.78)分,(74.69±9.11)分,t=-10.128,P=0.000],联合治疗组的Lysholm评分大于塞来昔布组(t=0.613,P=0.001)。2组患者治疗期间血、尿、大便常规检查,肝肾功能检查及心电图检查均未见异常,均未出现皮肤过敏症状。结论:紫车散外敷联合塞来昔布胶囊口服,能有效抑制湿热瘀闭型滑膜炎患者的炎症反应、减轻膝关节疼痛、改善膝关节功能,疗效优于单纯口服塞来昔布,而且具有较高的安全性。
Abstract:
ABSTRACT Objective:To observe the clinical curative effects and safety of external application of Ziche San(紫车散,ZCS)combined with oral application of celecoxib capsules for treatment of gonarthromeningitis with syndrome of BLOCKADE of DAMP-HEAT and STATIC BLOOD(湿热瘀闭,BDHSB).Methods:Sixty-three patients with BDHSB-type gonarthromeningitis were enrolled in the study andwere randomly divided into 2 groups,28 cases in combination therapy group and 35 cases in celecoxib group.The patients in combination therapy group were treated with external application of ZCS combined with oral application of celecoxib capsules,while the patients in celecoxib group were treated with monotherapy of oral application of celecoxib capsules for consecutive 4 weeks.Erythrocyte sedimentation rates(ESR),hypersensitive C-reactive protein(hs-CRP)levels,knee pain visual analogue scale(VAS)scores and Lysholm knee scores were measured and compared between the 2 groups before treatment and after the end of the treatment respectively,and the complication rates were observed during the treatment period.Results:There was no statistical difference in ESR between the 2 groups before the treatment(t=0.077,P=0.567).The ESR decreased in both of the 2 groups after the end of the treatment(36.04+/-11.04 vs 11.61+/-6.30 mm/h,t=13.818,P=0.000; 34.37+/-11.02 vs 17.23+/-7.45 mm/h,t=10.411,P=0.000),and the ESR were lower in combination therapy group compared to celecoxib group(t=1.480,P=0.002).There was no statistical difference in hs-CRP levels between the 2 groups before the treatment(t=0.201,P=0.691).The hs-CRP levels decreased in both of the 2 groups after the end of the treatment(40.57+/-11.73 vs 7.39+/-2.31 mg/l,t=15.599,P=0.000; 39.37+/-11.96 vs 16.91+/-6.68 mg/l,t=9.936,P=0.000),and the hs-CRP levels were lower in combination therapy group compared to celecoxib group(t=26.264,P=0.000).There was no statistical difference in knee pain VAS scores between the 2 groups before the treatment(t=0.129,P=0.657).The VAS scores decreased in both of the 2 groups after the end of the treatment(6.54+/-1.62 vs 1.93+/-0.22 points,t=10.827,P=0.000; 6.71+/-1.55 vs 2.74+/-0.60 points,t=13.398,P=0.000),and the VAS scores were lower in combination therapy group compared to celecoxib group(t=2.333,P=0.029).There was no statistical difference in Lysholm knee scores between the 2 groups before the treatment(t=0.306,P=0.826).The Lysholm knee scores increased in both of the 2 groups after the end of the treatment(54.04+/-12.56 vs 82.36+/-7.99 points,t=-8.908,P=0.000; 54.71+/-11.78 vs 74.69+/-9.11 points,t=-10.128,P=0.000),and the Lysholm knee scores were higher in combination therapy group compared to celecoxib group(t=0.613,P=0.001).The routine examination results of blood,urine,stool,hepatorenal function and electrocardiography were normal and no skin allergy symptom was found in both of the 2 groups during the treatment period.Conclusion:The combination therapy of external application of ZCS and oral application of celecoxib capsules can effectively inhibit the inflammatory reaction,relieve the knee pain and improve the knee function in patients with BDHSB-type gonarthromeningitis,and its curative effect is better than that of monotherapy of oral application of celecoxib capsules,meanwhile,it has high safety.

参考文献/References:

[1] 乔登朝,王少华,白玉,等.塞来昔布联合三七消肿止痛散治疗创伤性膝关节滑膜炎临床观察[J].风湿病与关节炎,2017,6(4):25-28.
[2] BILTHARIYA U,JAIN N,RAJORIYA V,et al.Folate-conjugated albumin nanoparticles for rheumatoid arthritis-targeted delivery of etoricoxib[J].Drug Dev Ind Pharm,2015,41(1):95-104.
[3] 吴震,童培建,张培祥,等.张氏膝痛方联合塞来昔布胶囊口服治疗湿热阻络型膝关节滑膜炎的临床研究[J].中医正骨,2017,29(4):13-15.
[4] BHOSALE UA,QURAISHI N,YEGNANARAYAN R,et al.A cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors(COX-Is)in arthritic patients attending orthopedic department of a tertiary care hospital[J].Niger Med J,2014,55(5):417-422.
[5] 贾丽芳.中西医结合治疗膝关节滑膜炎的研究新进展[J].北方药学,2013,10(3):49-50.
[6] 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994:197.
[7] LYSHOLM J,GILLQUIST J.Evaluation of knee ligament surgery results with special emphasis on use of a scoring scale[J].Am J Sports Med,1982,10(3):150-154.
[8] 吴欢,占远,陈海芳.UHPLC-ESI-Q-TOF-MS/MS对紫花地丁中化学成分的快速表征[J].中国实验方剂学杂志,2016,22(24):70-75.
[9] 宋妍.紫花地丁苗理作用的研究现状[J].中医临床研究,2017,9(12):136-137.
[10] 王芳芳,潘竞先,欧阳飚.基于分子对接的车前草抗炎机制研究[J].中医药学报,2012,40(2):78-81.
[11] 李永生,何希瑞,杨燕,等.紫花地丁化学成分与药理活性研究新进展[J].环球中医药,2013,6(4):313-318.
[12] 黄桃芬,卢丹逸,喻芳君,等.HPLC法同时测定车前草中4种成分的含量[J].中草药,2017,40(3):645-648.
[13] 林云,江林,蒋健,等.蒲公英的药理作用研究进展[J].中国现代中药,2011,13(8):42-47.
[14] 张汉庆,肖嫚,刘勇.单味中药治疗骨性关节炎研究进展[J].中国中医骨伤科杂志,2012,20(1):65-67.
[15] 吴剑,鲍同柱,肖长义,等.栀子对兔膝骨关节炎模型关节软骨病理改变及IL-1 β表达的影响[J].第二军医大学学报,2009,30(3):329-331.
[16] 辛卫云,苗明三.泽兰的化学、药理及临床应用[J].中医学报,2015,30(3):418-420.
[17] 杨炀,税丕先,陈滟,等.中药大黄在临床应用中的功效以及对其药理作用[J].基因组学与应用生物学,2017,36(3):1226-1231.
[18] 陈燕文,胡晶红,李佳,等.金银花多糖提取,精制方法和药理活性综述[J].辽宁中医药大学学报,2017,19(1):155-159.
[19] 王莹,褚扬,李伟,等.三七中皂苷成分及其药理作用的研究进展[J].中草药,2015,46(9):1381-1392.
[20] 张轩,周斌,路慧丽.草乌甲素的药理作用机制及临床应用研究进展[J].慢性病学杂志,2016,17(11):1210-1213.
[21] 蔡卓亚,周自桂,李萍,等.伸筋草化学成分及药理作用研究进展[J].中草药,2015,46(2):297-304.
[22] 李瑞龙,张强,杨刘柱,等.盘龙七片治疗急性腰背部软组织损伤31例[J].中国中医骨伤科杂志,2017,25(4):75-76.

相似文献/References:

[1]邓伟哲,王宏晶,王宇恒,等.微创针刀镜治疗难治性膝关节类风湿关节炎[J].中医正骨,2015,27(11):42.
[2]李楠,李锋.胫骨平台骨折的手术治疗进展[J].中医正骨,2015,27(12):78.
[3]陈利军,田野,刘文刚,等.非典型膝关节外伤后胫骨近端隐匿性骨折的影像诊断[J].中医正骨,2015,27(06):26.
[4]汤金城,谭旭仪,成传德.前外侧切口可吸收螺钉内固定治疗Hoffa骨折[J].中医正骨,2015,27(03):44.
[5]刘道兵,周宇,谢斌,等.关节镜下滑膜切除术联合中药口服 治疗膝关节色素沉着绒毛结节性滑膜炎[J].中医正骨,2013,25(09):34.
[6]张阿雷.关节囊外复位内固定治疗胫骨平台骨折[J].中医正骨,2016,28(01):54.
[7]李延红,石耀武,张宏蕾.外敷滑膜膏配合口服四妙丸治疗踝关节滑膜炎[J].中医正骨,2016,28(01):68.
[8]路怀民,谭佳汶,刘蓓,等.运动疗法联合中医综合疗法治疗早期创伤性半月板损伤[J].中医正骨,2016,28(03):68.
[9]赵进征,吴旭东,黄小刚,等.同种异体肌腱移植治疗膝关节后外侧角损伤[J].中医正骨,2016,28(09):40.
[10]杨小广,杨乔辉,刘长风,等.胫骨平台骨折切开复位内固定术后膝关节功能恢复的影响因素分析[J].中医正骨,2016,28(10):11.
　YANG Xiaoguang,YANG Qiaohui,LIU Changfeng,et al.Analysis of factors influencing knee function recovery after open reduction and internal fixation for treatment of tibial plateau fractures[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(10):11.
[11]赵新杰,孙实,武爱玲.中医药治疗膝关节滑膜炎的研究进展[J].中医正骨,2015,27(08):65.
[12]郑昱新,詹红生,莫文,等.滑膜炎颗粒治疗膝关节滑膜炎湿热阻络证的随机、 双盲、安慰剂对照、多中心临床研究[J].中医正骨,2015,27(12):29.
　ZHENG Yuxin,ZHAN Hongsheng,MO Wen,et al.A randomized,double-blind,placebo-controlled,multicenter,clinical trial of Huamoyan Keli(滑膜炎颗粒)for treatment of gonarthromeningitis with DAMPNESS-HEAT BLOCK COLLATERALS syndrome[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(10):29.
[13]赫军,李冬冬,禹建春,等.口服狐惑蠲痹汤和西药治疗贝赫切特综合征膝关节滑膜炎湿热瘀阻证[J].中医正骨,2019,31(03):51.
[14]彭德强,林志东,钟礼伦,等.全膝关节置换术与关节镜下滑膜切除术治疗晚期膝关节色素沉着绒毛结节性滑膜炎的Meta分析[J].中医正骨,2022,34(01):50.
　PENG Deqiang,LIN Zhidong,ZHONG Lilun,et al.Comparison of total knee arthroplasty and arthroscopic synovectomy for treatment of terminal knee pigmented villonodular synovitis:a meta analysis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2022,34(10):50.

备注/Memo

备注/Memo:
通讯作者:张礼平 E-mail:1289192117@qq.com
更新日期/Last Update: 2018-03-10